Literature DB >> 28109042

Expression and characterization of a codon-optimized blood coagulation factor VIII.

S A Shestopal1, J-J Hao2, E Karnaukhova1, Y Liang1, M V Ovanesov1, M Lin1, J H Kurasawa1, T K Lee1, J H Mcvey3, A G Sarafanov1.   

Abstract

Essentials Recombinant factor VIII (FVIII) is known to be expressed at a low level in cell culture. To increase expression, we used codon-optimization of a B-domain deleted FVIII (BDD-FVIII). This resulted in 7-fold increase of the expression level in cell culture. The biochemical properties of codon-optimized BDD-FVIII were similar to the wild-type protein.
SUMMARY: Background Production of recombinant factor VIII (FVIII) is challenging because of its low expression. It was previously shown that codon-optimization of a B-domain-deleted FVIII (BDD-FVIII) cDNA resulted in increased protein expression. However, it is well recognized that synonymous mutations may affect the protein structure and function. Objectives To compare biochemical properties of a BDD-FVIII variants expressed from codon-optimized and wild-type cDNAs (CO and WT, respectively). Methods Each variant of the BDD-FVIII was expressed in several independent Chinese hamster ovary (CHO) cell lines, generated using a lentiviral platform. The proteins were purified by two-step affinity chromatography and analyzed in parallel by PAGE-western blot, mass spectrometry, circular dichroism, surface plasmon resonance, and chromogenic, clotting and thrombin generation assays. Results and conclusion The average yield of the CO was 7-fold higher than WT, whereas both proteins were identical in the amino acid sequences (99% coverage) and very similar in patterns of the molecular fragments (before and after thrombin cleavage), glycosylation and tyrosine sulfation, secondary structures and binding to von Willebrand factor and to a fragment of the low-density lipoprotein receptor-related protein 1. The CO preparations had on average 1.5-fold higher FVIII specific activity (activity normalized to protein mass) than WT preparations, which was attributed to better preservation of the CO structure as a result of considerably higher protein concentrations during the production. We concluded that the codon-optimization of the BDD-FVIII resulted in significant increase of its expression and did not affect the structure-function properties.
© 2017 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  LRP1 protein, human; coagulation factor VIII; hemophilia A; lentivirus; von Willebrand factor

Mesh:

Substances:

Year:  2017        PMID: 28109042     DOI: 10.1111/jth.13632

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  9 in total

1.  FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity.

Authors:  Ruth A Ettinger; Joseph A Liberman; Devi Gunasekera; Komal Puranik; Eddie A James; Arthur R Thompson; Kathleen P Pratt
Journal:  Blood Adv       Date:  2018-02-27

2.  Molecular mechanisms of missense mutations that generate ectopic N-glycosylation sites in coagulation factor VIII.

Authors:  Wei Wei; Saurav Misra; Matthew V Cannon; Renchi Yang; Xiaofan Zhu; Reid Gilmore; Min Zhu; Bin Zhang
Journal:  Biochem J       Date:  2018-03-06       Impact factor: 3.857

3.  Long-term correction of hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid FVIII composed of the human heavy chain and the rat light chain.

Authors:  Jianhua Mao; Yun Wang; Wei Zhang; Yan Shen; Guowei Zhang; Wenda Xi; Qiang Wang; Zheng Ruan; Jin Wang; Xiaodong Xi
Journal:  Front Med       Date:  2022-01-17       Impact factor: 9.927

Review 4.  Production of Therapeutic Enzymes by Lentivirus Transgenesis.

Authors:  María Celeste Rodríguez; Natalia Ceaglio; Sebastián Antuña; María Belén Tardivo; Marina Etcheverrigaray; Claudio Prieto
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

5.  Mechanistic Insights into Factor VIII Immune Tolerance Induction via Prenatal Cell Therapy in Hemophilia A.

Authors:  Martin Rodriguez; Christopher D Porada; Graҫa Almeida-Porada
Journal:  Curr Stem Cell Rep       Date:  2019-11-20

6.  Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII.

Authors:  Jenni Firrman; Qizhao Wang; Wenman Wu; Biao Dong; Wenjing Cao; Andrea Rossi Moore; Sean Roberts; Barbara A Konkle; Carol Miao; LinShu Liu; Dong Li; Weidong Xiao
Journal:  Mol Ther Methods Clin Dev       Date:  2020-01-15       Impact factor: 6.698

7.  Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency.

Authors:  Wenjing Cao; Biao Dong; Franziska Horling; Jenni A Firrman; Johannes Lengler; Matthias Klugmann; Maurus de la Rosa; Wenman Wu; Qizhao Wang; Hongying Wei; Andrea R Moore; Sean A Roberts; Carmen J Booth; Werner Hoellriegl; Dong Li; Barbara Konkle; Carol Miao; Birgit M Reipert; Friedrich Scheiflinger; Hanspeter Rottensteiner; Weidong Xiao
Journal:  Mol Ther Methods Clin Dev       Date:  2020-10-22       Impact factor: 6.698

Review 8.  Immune Responses to Plasma-Derived Versus Recombinant FVIII Products.

Authors:  Flora Peyvandi; Syna Miri; Isabella Garagiola
Journal:  Front Immunol       Date:  2021-01-22       Impact factor: 7.561

Review 9.  Emerging therapies for hemophilia: controversies and unanswered questions.

Authors:  Valder R Arruda; Bhavya S Doshi; Benjamin J Samelson-Jones
Journal:  F1000Res       Date:  2018-04-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.